"Amyloidosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Descriptor ID |
D000686
|
MeSH Number(s) |
C18.452.845.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Amyloidosis".
Below are MeSH descriptors whose meaning is more specific than "Amyloidosis".
This graph shows the total number of publications written about "Amyloidosis" by people in this website by year, and whether "Amyloidosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 2 | 3 |
1996 | 2 | 1 | 3 |
1997 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 0 | 1 | 1 |
2003 | 2 | 0 | 2 |
2004 | 1 | 0 | 1 |
2005 | 1 | 1 | 2 |
2006 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2009 | 2 | 0 | 2 |
2010 | 3 | 0 | 3 |
2011 | 1 | 1 | 2 |
2012 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
2014 | 2 | 1 | 3 |
2016 | 2 | 0 | 2 |
2017 | 1 | 1 | 2 |
2018 | 3 | 1 | 4 |
2019 | 1 | 0 | 1 |
2020 | 4 | 2 | 6 |
2021 | 2 | 1 | 3 |
2022 | 4 | 0 | 4 |
2023 | 9 | 0 | 9 |
2024 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amyloidosis" by people in Profiles.
-
Perivascular Amyloid Deposition in Immunoglobulin Light Chain Cardiac Amyloidosis and Its Implications on Echocardiographic Cardiac Remodeling. J Am Soc Echocardiogr. 2024 Oct; 37(10):1010-1012.
-
Paraprotein-Mediated Glomerular Diseases. Adv Kidney Dis Health. 2024 Jul; 31(4):358-373.
-
Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype. Curr Probl Cardiol. 2024 Sep; 49(9):102729.
-
As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis. J Am Coll Cardiol. 2024 Jun 18; 83(24):2423-2425.
-
Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study. Eur Heart J Cardiovasc Imaging. 2024 05 31; 25(6):754-761.
-
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner. Mol Neurodegener. 2024 Feb 17; 19(1):18.
-
Prevalence of valvular heart disease in cardiac amyloidosis and impact on survival. Curr Probl Cardiol. 2024 Apr; 49(4):102417.
-
Translational profiling identifies sex-specific metabolic and epigenetic reprogramming of cortical microglia/macrophages in APPPS1-21 mice with an antibiotic-perturbed-microbiome. Mol Neurodegener. 2023 Dec 16; 18(1):95.
-
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 Oct 26; 389(17):1553-1565.
-
Preservation of Circumferential and Radial Left Ventricular Function as a Mitigating Mechanism for Impaired Longitudinal Strain in Early Cardiac Amyloidosis. J Am Soc Echocardiogr. 2023 12; 36(12):1290-1301.